JP2019510069A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019510069A5 JP2019510069A5 JP2018551785A JP2018551785A JP2019510069A5 JP 2019510069 A5 JP2019510069 A5 JP 2019510069A5 JP 2018551785 A JP2018551785 A JP 2018551785A JP 2018551785 A JP2018551785 A JP 2018551785A JP 2019510069 A5 JP2019510069 A5 JP 2019510069A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- formula
- group
- aryl
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 130
- 125000003118 aryl group Chemical group 0.000 claims description 30
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 229910052801 chlorine Inorganic materials 0.000 claims description 21
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 18
- 229910052805 deuterium Inorganic materials 0.000 claims description 17
- 229910052731 fluorine Inorganic materials 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 16
- 125000001072 heteroaryl group Chemical group 0.000 claims description 15
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 9
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000005842 heteroatom Chemical group 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 208000026310 Breast neoplasm Diseases 0.000 claims 3
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 3
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 3
- 206010033128 Ovarian cancer Diseases 0.000 claims 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 201000010536 head and neck cancer Diseases 0.000 claims 3
- 208000014829 head and neck neoplasm Diseases 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 3
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 3
- 101150025421 ETS gene Proteins 0.000 claims 2
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 206010046766 uterine cancer Diseases 0.000 claims 2
- 102100039563 ETS translocation variant 1 Human genes 0.000 claims 1
- 102100039578 ETS translocation variant 4 Human genes 0.000 claims 1
- 102100030334 Friend leukemia integration 1 transcription factor Human genes 0.000 claims 1
- 101001077417 Gallus gallus Potassium voltage-gated channel subfamily H member 6 Proteins 0.000 claims 1
- 101000813729 Homo sapiens ETS translocation variant 1 Proteins 0.000 claims 1
- 101000813747 Homo sapiens ETS translocation variant 4 Proteins 0.000 claims 1
- 101001062996 Homo sapiens Friend leukemia integration 1 transcription factor Proteins 0.000 claims 1
- 101000893493 Homo sapiens Protein flightless-1 homolog Proteins 0.000 claims 1
- 101001010792 Homo sapiens Transcriptional regulator ERG Proteins 0.000 claims 1
- 102100022807 Potassium voltage-gated channel subfamily H member 2 Human genes 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 210000004291 uterus Anatomy 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021053887A JP7269668B2 (ja) | 2016-03-31 | 2021-03-26 | インドール類似体及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662316156P | 2016-03-31 | 2016-03-31 | |
| US62/316,156 | 2016-03-31 | ||
| US201662417621P | 2016-11-04 | 2016-11-04 | |
| US62/417,621 | 2016-11-04 | ||
| PCT/US2017/022682 WO2017172368A1 (en) | 2016-03-31 | 2017-03-16 | Indoline analogs and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021053887A Division JP7269668B2 (ja) | 2016-03-31 | 2021-03-26 | インドール類似体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510069A JP2019510069A (ja) | 2019-04-11 |
| JP2019510069A5 true JP2019510069A5 (https=) | 2020-04-09 |
| JP6864379B2 JP6864379B2 (ja) | 2021-04-28 |
Family
ID=59960688
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551785A Active JP6864379B2 (ja) | 2016-03-31 | 2017-03-16 | インドール類似体及びその使用 |
| JP2021053887A Active JP7269668B2 (ja) | 2016-03-31 | 2021-03-26 | インドール類似体及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021053887A Active JP7269668B2 (ja) | 2016-03-31 | 2021-03-26 | インドール類似体及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US9822122B2 (https=) |
| EP (2) | EP3795563B1 (https=) |
| JP (2) | JP6864379B2 (https=) |
| KR (2) | KR102375929B1 (https=) |
| CN (1) | CN109219594B (https=) |
| AR (1) | AR108010A1 (https=) |
| DK (1) | DK3436434T3 (https=) |
| ES (1) | ES2823190T3 (https=) |
| TW (2) | TWI786723B (https=) |
| WO (1) | WO2017172368A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107108580B (zh) | 2014-10-09 | 2020-06-30 | 英克特诺治疗公司 | 吲哚酮化合物及其用途 |
| EP3795563B1 (en) * | 2016-03-31 | 2024-07-17 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
| CA3029851A1 (en) | 2016-07-29 | 2018-02-01 | Oncternal Therapeutics, Inc. | Uses of indoline compounds such as tk216 for the treatment of cancer |
| TR202002324A2 (tr) * | 2020-02-17 | 2021-08-23 | Bahcesehir Ueniversitesi | Yeni̇ mouse double minute 2 (mdm2) i̇nhi̇bi̇törü olarak kullanmak i̇çi̇n drg-mdm2-3 |
| CN111518086B (zh) * | 2020-05-22 | 2021-08-06 | 广州医科大学 | 氧化吲哚-萘并呋喃衍生物及其制备方法、用途以及包含其的药物组合物、制剂 |
| US20250361227A1 (en) * | 2022-03-13 | 2025-11-27 | University Of Virginia Patent Foundation | Inhibitors of fli1 and erg |
| CN115850151A (zh) * | 2022-11-25 | 2023-03-28 | 成都普康生物科技有限公司 | 一种席夫碱类似化合物及其合成方法、pi3k激酶抑制剂及其应用 |
| CN115993455A (zh) * | 2022-12-29 | 2023-04-21 | 南京医科大学康达学院 | Rna结合蛋白nova2作为非小细胞肺癌转移标志物的应用 |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3435034A (en) | 1967-03-17 | 1969-03-25 | Sandoz Ag | Pyridazino(3,4-b)indoles |
| US3631177A (en) | 1967-04-18 | 1971-12-28 | Smith Kline French Lab | 3-phenacyl-2-oxoindolines |
| US3592813A (en) | 1967-04-18 | 1971-07-13 | Smith Kline French Lab | 3-phenyl-9h-pyridazino(3,4-b)indoles |
| US4376731A (en) | 1978-01-31 | 1983-03-15 | Boehringer Mannheim Gmbh | 1-Aziridine carboxylic acid derivatives with immunostimulant activity |
| AU583793B2 (en) | 1983-07-22 | 1989-05-11 | Du Pont Pharmaceuticals Company | Phenylquinolinecarboxylic acids and derivatives as antitumor agents |
| KR910700237A (ko) | 1989-01-23 | 1991-03-14 | 리챠드 지. 워터맨 | 치환된 트리아졸, 그의 제조방법 및 살진균제로서 사용하기 위한 조성물 |
| GB8909737D0 (en) | 1989-04-27 | 1989-06-14 | Shell Int Research | Thiazole derivatives |
| US5750542A (en) | 1993-09-28 | 1998-05-12 | Pfizer | Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors |
| EP0613890A1 (en) | 1993-02-28 | 1994-09-07 | Nihon Nohyaku Co., Ltd. | Novel triazole compound, process for preparing the same and antifungal agent containing the same |
| CA2190708A1 (en) | 1995-12-08 | 1997-06-09 | Johannes Aebi | Aminoalkyl substituted benzo-heterocyclic compounds |
| AU7108398A (en) | 1997-04-16 | 1998-11-11 | Abbott Laboratories | 5,7-disubstituted 4-aminopyrido{2,3-d}pyrimidine compounds and their use as adenosine kinase inhibitors |
| EP1135123B1 (en) | 1998-12-04 | 2004-12-29 | Neurosearch A/S | Use of isatin derivatives as ion channel activating agents |
| CN1155572C (zh) | 2001-01-19 | 2004-06-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| US20030114666A1 (en) | 2001-06-19 | 2003-06-19 | Ellsworth Edmund Lee | Antibacterial agents |
| US20030157486A1 (en) | 2001-06-21 | 2003-08-21 | Graff Jonathan M. | Methods to identify signal sequences |
| GB0219687D0 (en) | 2002-08-23 | 2002-10-02 | Lilly Co Eli | Benzyl morpholine derivatives |
| US7674778B2 (en) | 2004-04-30 | 2010-03-09 | Alnylam Pharmaceuticals | Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine |
| EP1753754A1 (en) | 2004-05-25 | 2007-02-21 | AstraZeneca AB | 3- '4- {6-substituted alkanoyl) pyridin-3-yl} -3-phenyl! -5- (1h-1, 2, 3-triazol-1-ylmethyl) -1, 3-oxazolidin-2-ones as antibacterial agents |
| JP2008500318A (ja) | 2004-05-25 | 2008-01-10 | アストラゼネカ アクチボラグ | 抗菌剤としての３−｛４−（ピリジン−３−イル）フェニル｝−５−（１ｈ−１，２，３−トリアゾール−１−イルメチル）−１，３−オキサゾリジン−２−オン |
| EP1871766A4 (en) | 2005-03-30 | 2010-07-21 | Dae Woong Pharma | TRIAZONE DERIVATIVES WITH ANTIPILY EFFECT |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| US20090217390A1 (en) | 2005-04-29 | 2009-08-27 | Fernando Lecanda Cordero | Non-human animal sarcoma model |
| CA2610588A1 (en) | 2005-06-10 | 2006-12-21 | Boehringer Ingelheim International Gmbh | Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| CA2620878A1 (en) | 2005-08-29 | 2007-04-05 | Gerard M. Housey | Theramutein modulators |
| FR2903984B1 (fr) | 2006-07-24 | 2008-10-03 | Genfit Sa | Derives d'imidazolones substitues, preparation et utilisations |
| WO2008046083A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| CA2953987A1 (en) | 2006-12-29 | 2008-07-10 | Georgetown University | Targeting of ews-fli1 as anti-tumor therapy |
| WO2008091681A2 (en) | 2007-01-23 | 2008-07-31 | Housey Gerard M | Theramutein modulators |
| CA2679657A1 (en) | 2007-03-02 | 2008-09-12 | Micurx Pharmaceuticals, Inc. | Antimicrobial heterocyclic compounds for treatment of bacterial infections |
| MX2009011281A (es) | 2007-04-20 | 2010-03-08 | Univ New York State Res Found | Benzimidazol y composiciones farmaceuticas del mismo. |
| US8377992B2 (en) | 2007-10-22 | 2013-02-19 | The Wistar Institute | TRBD-binding effectors and methods for using the same to modulate telomerase activity |
| WO2010019910A1 (en) | 2008-08-15 | 2010-02-18 | N30 Pharmaceuticals, Llc | Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents |
| WO2010033643A2 (en) | 2008-09-17 | 2010-03-25 | Burnham Institute For Medical Research | Small molecule compounds for stem cell differentiation |
| US20110218155A1 (en) | 2008-10-10 | 2011-09-08 | Dana-Farber Cancer Institute, Inc. | Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides |
| AU2009308516B2 (en) | 2008-10-21 | 2016-08-25 | Onyx Therapeutics, Inc. | Combination therapy with peptide epoxyketones |
| US8710068B2 (en) * | 2009-01-19 | 2014-04-29 | The Trustees Of The University Of Pennsylvania | Method of treating cancer using a survivin inhibitor |
| KR101149529B1 (ko) | 2009-09-11 | 2012-05-25 | 한국화학연구원 | 인덴온 유도체 및 이를 포함하는 약학적 조성물 |
| US9156822B2 (en) | 2010-07-02 | 2015-10-13 | The University Of North Carolina At Chapel Hill | Functionally selective ligands of dopamine D2 receptors |
| CA2807815C (en) | 2010-08-10 | 2018-10-02 | Metabolic Solutions Development Company, Llc | Novel synthesis for thiazolidinedione compounds |
| WO2012078519A2 (en) | 2010-12-06 | 2012-06-14 | Numerate, Inc. | 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2 |
| IN2014MN00093A (https=) | 2011-06-19 | 2015-06-19 | Viamet Pharmaceuticals Inc | |
| CN102516152B (zh) | 2011-12-12 | 2014-12-10 | 华东师范大学 | 一种α-二氟羰基取代的手性叔醇类化合物及其合成方法和应用 |
| US9399645B2 (en) | 2011-12-20 | 2016-07-26 | Boehringer Ingelheim International Gmbh | Inhibitors of HIV replication |
| WO2013144224A1 (en) | 2012-03-27 | 2013-10-03 | Syngenta Participations Ag | Acetylenic microbiocides |
| US20130259927A1 (en) | 2012-04-02 | 2013-10-03 | Gradalis, Inc. | Ewing's Sarcoma Bifunctional shRNA Design |
| CN107011242B (zh) | 2012-04-12 | 2020-08-07 | 乔治城大学 | 用于治疗尤文肉瘤家族肿瘤的方法和组合物 |
| MX2015000804A (es) * | 2012-07-20 | 2016-03-11 | Star Biotechnology Llc | Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1. |
| AU2013305759C1 (en) | 2012-08-23 | 2018-01-18 | Janssen Biopharma, Inc. | Compounds for the treatment of paramoxyvirus viral infections |
| TWI687220B (zh) | 2013-03-01 | 2020-03-11 | 美商英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途 |
| WO2014152144A1 (en) | 2013-03-15 | 2014-09-25 | Acadia Pharmaceuticals Inc. | Muscarinic agonists |
| US9593113B2 (en) | 2013-08-22 | 2017-03-14 | Bristol-Myers Squibb Company | Imide and acylurea derivatives as modulators of the glucocorticoid receptor |
| CN103435606A (zh) | 2013-08-22 | 2013-12-11 | 中国药科大学 | CDK2与GSK3β双重抑制剂及用途 |
| AU2014340398A1 (en) | 2013-10-24 | 2016-06-09 | Georgetown University | Methods and compositions for treating cancer |
| CN105960239A (zh) | 2013-11-27 | 2016-09-21 | 翁科埃斯克斯有限公司 | 利用含有噻吩并三唑并二氮杂*化合物的药物制剂治疗白血病的方法 |
| WO2015082583A1 (en) | 2013-12-05 | 2015-06-11 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| SG11201607392SA (en) | 2014-03-07 | 2016-10-28 | Bristol Myers Squibb Co | Dihydropyridinone mgat2 inhibitors for use in the treatment of metabolic disorders |
| EP3131552B1 (en) | 2014-04-16 | 2020-07-15 | Signal Pharmaceuticals, LLC | Methods for treating cancer using tor kinase inhibitor combination therapy |
| CA2961356C (en) | 2014-09-15 | 2023-03-07 | Plexxikon Inc. | Heterocyclic compounds and their uses in modulating bromodomain and for treating diseases or conditions relevant thereto |
| CN107108580B (zh) | 2014-10-09 | 2020-06-30 | 英克特诺治疗公司 | 吲哚酮化合物及其用途 |
| EP3795563B1 (en) | 2016-03-31 | 2024-07-17 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
| CA3029851A1 (en) | 2016-07-29 | 2018-02-01 | Oncternal Therapeutics, Inc. | Uses of indoline compounds such as tk216 for the treatment of cancer |
-
2017
- 2017-03-16 EP EP20184572.4A patent/EP3795563B1/en active Active
- 2017-03-16 JP JP2018551785A patent/JP6864379B2/ja active Active
- 2017-03-16 US US15/461,327 patent/US9822122B2/en active Active
- 2017-03-16 WO PCT/US2017/022682 patent/WO2017172368A1/en not_active Ceased
- 2017-03-16 EP EP17776297.8A patent/EP3436434B1/en active Active
- 2017-03-16 CN CN201780034085.7A patent/CN109219594B/zh active Active
- 2017-03-16 KR KR1020187031059A patent/KR102375929B1/ko active Active
- 2017-03-16 ES ES17776297T patent/ES2823190T3/es active Active
- 2017-03-16 DK DK17776297.8T patent/DK3436434T3/da active
- 2017-03-16 KR KR1020227008510A patent/KR102514814B1/ko active Active
- 2017-03-30 TW TW110125866A patent/TWI786723B/zh active
- 2017-03-30 AR ARP170100787A patent/AR108010A1/es unknown
- 2017-03-30 TW TW106110666A patent/TWI793070B/zh active
- 2017-08-18 US US15/680,905 patent/US10351569B2/en active Active
-
2019
- 2019-06-03 US US16/430,234 patent/US10711008B2/en active Active
-
2021
- 2021-03-26 JP JP2021053887A patent/JP7269668B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019510069A5 (https=) | ||
| RU2477723C2 (ru) | Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе | |
| JP2008535902A5 (https=) | ||
| KR930702292A (ko) | 종양 치료 활성을 증대시키기 위한 퀴나졸린 유도체 | |
| JP2019513770A5 (https=) | ||
| JP2019512478A5 (https=) | ||
| JP2008535903A5 (https=) | ||
| KR20010102519A (ko) | 항 종양 활성을 갖는 캠토테신 유도체 | |
| ES2564257T3 (es) | Nuevos análogos de piperazina con grupos heteroarilo sustituidos como antivirales de amplio espectro de la gripe | |
| JPH06500117A (ja) | 抗腫瘍活性を増強させる２，４−ジアミノキナゾリン誘導体 | |
| RU2020102453A (ru) | Фармацевтические композиции | |
| JP2015512943A5 (https=) | ||
| CA2485430A1 (en) | Process for the preparation of a hydrate of an anthranilic acid derivative | |
| JP2012526766A5 (https=) | ||
| CN102887904B (zh) | 2,3-二氧乙基-5-甲基-8,9-二甲氧基苯并菲啶衍生物及其制备方法和应用 | |
| JP2009530392A5 (https=) | ||
| CN113087712B (zh) | L-氨基酸-6-胶霉毒素酯三氟乙酸盐及其制备方法 | |
| WO2013178021A1 (zh) | 吡咯并[2，1—f][1，2，4]三嗪衍生物及其抗肿瘤用途 | |
| JP2017534657A (ja) | 新型シチジン誘導体およびその適用 | |
| AU2015303724B2 (en) | Quinazoline derivative | |
| JP2017523141A5 (https=) | ||
| JP2019504833A5 (https=) | ||
| JP2007532628A (ja) | エピポドフィロトキシンの（ポリ）アミノアルキルアミノアセトアミド誘導体、その調製方法及び諸療法における抗癌剤としてのその応用 | |
| CN106673988B (zh) | 苄亚基环己烯酮衍生物及其制备方法和医药用途 | |
| JP2020517676A5 (https=) |